Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population.

J P SevillaJessica M KlustyYounghwan SongMark J RussoChristin A ThompsonXiayu JiaoSeth J ClancyDavid E Bloom

Published in: Journal of medical economics (2022)

Across risk-, age-, and treatment-eligibility groups, TAVR is the economically optimal treatment choice. It represents strong value-for-money per patient and population-wide. The vast majority of TAVR value involves raising treatment uptake among the untreated.

Keyphrases

aortic stenosis
transcatheter aortic valve replacement
aortic valve
aortic valve replacement
left ventricular
transcatheter aortic valve implantation
case report
heart failure
early onset
atrial fibrillation